April 16th 2024
Amid lingering questions and uncertainty, a look at ways pharma companies can prioritize incorporating the Inflation Reduction Act into their strategic planning process—and do it now.
Managing the 3 Fronts of the Drug Pricing Conundrum: Policy, Creativity, Collaboration
August 27th 2019The impacts of disruptive curative therapies and advances in the future of health will be profound. To be best positioned for success, healthcare systems under continuous cost pressure must address three key areas, writes Thomas Unger.
Outcomes-Based Contracting: The Next Step to Better Patient Care
July 1st 2019While there are challenges at every turn, the promise of outcomes-based contracting is a level of care for patients that might otherwise not be possible, while striking the right balance of benefits and risks for all parties involved, writes Melonie Warfel.
Value-Based Purchasing for Prescription Drugs Takes a Leap Forward in State Medicaid
June 29th 2018The U.S. Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) are commitment to support value-based purchasing (VBP) of prescription drugs in Medicaid, despite headlines of CMS’s rejection of a Massachusetts request to make changes in its Medicaid prescription drug benefit.